Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Aug 16, 2022 10:11am
120 Views
Post# 34899104

RE:RE:RE:RE:RE:September expectations

RE:RE:RE:RE:RE:September expectations

It's the CRO's job to manage the sites. It's Christian's job to pressure the CRO but there's no evidence that recruitment is slow.

You're not understanding that NASH is not the same prospect it was when they started this process. Listen to NASH KOL's.

I think you're completely misunderstand what he meant by socializing. He was talking about greater engagement with docs and patients within the boundaries of the label.

I don't see many clinical developments that could turn around Trogarzo. Not in the short term. The market is just not there.

Your date might be meaningful to you but I don't see it being a pivotal moment for the company. I don't see any of the business milestones you talk about fixed to that date.


Joemare wrote: We got to stop moving the line. September. Leadership is also getting the P.I. to recruit patients.  Really.  Has he gone to visit the sites? P.I.? Marsolais, how many times does he call the P.I.?? They need to deliver results in September.  If not, doubts start to trickle and patience will end for the few instutional investors left. 

NASH - 3 years with no returns on the effort. Delete the project from strategy or sell the rights to get a little cash.  Is he greedy or incapable to close a deal??  3 years with amazing P.II results and no-one in line. It's nothing to do with the water....come on.  You cannot ''ocialize" the drug, Mr. CEO. That's off-label and can bite you in the butt. And, you cannot measure that effect either. Impossible to measure the return on that 'socializing' effort. No script data on off-label use. 

China deal - really?? Flop or we have to wait?

You have ONE chance to successfully launch a pharmaceutical - TROGARZO is capped and will be unless a decent trial is published in LANCENT/JAMA/NEJM stating combo therapy is better.  He knows that.....

September is the delivery date. 30 days in September.

 

<< Previous
Bullboard Posts
Next >>